Compare Medpace Holdings Inc (MEDP) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Nasdaq Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Nasdaq Inc trades at $93.58 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 3.1× Medpace Holdings Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Nasdaq Inc for 126 Days on average.
| MEDP | NDAQ | |
|---|---|---|
Market Cap | $16.82B | $51.63B |
Volume | 223,093 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $630.19 | $100.98 |
52-Week Low | $393.42 | $76.85 |
Typical Hold Time | 14 Days | 126 Days |
Enterprise Value | $16.44B | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Nasdaq (NDAQ) trades at $93.51, up 1.72% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. Analyst consensus is a Buy with a $110.43 price target, supported by positive news on AI platform adoption and index changes.
Outlook remains positive given earnings momentum and Financial Technology growth, though risks include market volatility and debt levels. The stock offers upside to consensus targets but faces execution risks in tech integration and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
